ArticleTherapeutic advances in gastroenterology2025
Effectiveness of ustekinumab in Crohn's disease across intestinal locations: spotlight on isolated small intestinal involvement.
Article in Therapeutic advances in gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Small intestinal-predominant Crohn's disease (CD) exhibits distinct therapeutic patterns and is characterized by increased biological use and intestinal resection rates. However, systematic evaluations of the objective response of ustekinumab (UST), particularly related to disease location, are limited. Objectives: To compare the therapeutic efficacy of UST between small intestinal CD (SICD) and non-small intestinal CD (NSICD). Design: A prospective observational cohort study. Methods: Demographic and clinical characteristics were collected at baseline and 52-week follow-up, assessments including endoscopy, imaging, ultrasonography (US), histopathology, fecal calprotectin (FCP), C-reactive protein (CRP), and hemoglobin results. Patients with isolated ileal involvement (Montreal classification L1) were classified as having SICD, while NSICD was defined by L2 and L3. Primary outcome was objective remission, defined by meeting one of the following: (1) endoscopic remission (ER): Simple endoscopic score for CD (SES-CD) ⩽ 2. (2) US remission: normal bowel wall thickness and absence of Doppler signals or detectable complications, or (3) radiological remission: complete resolution of inflammatory features. Secondary outcomes included (1) mucosal healing (MH): absence of ulcerations. (2) transmural healing (TH): complete healing of all intestinal wall layers, and (3) biochemical remission: FCP/CRP normalization, (4) objective response: a clear improvement from baseline, and (5) endoscopic response: SES-CD ⩽ 4. Results: This study included 331 patients with CD (SICD 36.9%, NSICD 63.1%). Of these, 309 completed a 52-week follow-up. Objective remission, MH, and TH were achieved by 32.7%, 25.6%, and 13.6% of patients, respectively. Biochemical remission occurred in 41.5% (FCP) and 35.2% (CRP). Objective and endoscopic responses were observed in 70.2% and 42.1% of patients, respectively. Objective remission was achieved in 54/116 patients (46.6%) in the SICD group and 47/193 (24.4%) in the NSICD group. Regression analyses and propensity score matching showed significantly higher rates of objective remission, MH, and endoscopic response in the SICD group. Conclusion: Disease location influenced UST treatment outcomes, with SICD showing higher rates of objective remission, MH, and endoscopic response than NSICD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.